The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

The biannual AustinPx Amorphous Solid Dispersions (ASD) Workshop is a place for collaboration and innovation. Hear firsthand ...

Inductive Bio has secured up to $21m in funding from ARPA-H to lead the development of AI drug-toxicity prediction models.

Counterfeit pharmaceuticals jeopardize public health worldwide, often leading to ineffective or dangerous treatments. Enter ...

In a dramatic change to Australian patent law, Australia's Full Federal Court has just held that patents for pharmaceutical formulations are not eligible for patent term extensions ( PTE ): Otsuka ...

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic ...

First and Only AI-Simulated Roleplay Solution Exclusively Designed for Pharmaceutical Field Professionals, Awarded for AI Roleplay and Field Simulation Excellence ...

Nearly one in four European pharmaceutical companies remains vulnerable to regulatory risks due to inadequate quality systems ...

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...

Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery ...

Zhejiang Yangli Pharmaceutical Technology Co. Ltd. has synthesized thiazole-substituted pyrimidine amine compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer ...

The discovery, featured on the cover of Analytical Chemistry, could potentially slow the progression to full-blown diabetes.